Abstract:Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with surgery alone. However, since 2011, there has been an important revolution in the treatment of melanoma with new effective treatments. Targeted therapy and immunotherapy with checkpoint inhibitors have changed the history of this disease. To date, more than half of advanced melanoma patients are alive at 5 years; despite this breakthrough, approximately half of the patients still do not respond to treatment. For these reasons, new therapeutic strategies are required to expand the number of patients who can benefit from immunotherapy or combination with targeted therapy. Current research aims at preventing primary and acquired resistance, which are both responsible for treatment failure in about 50% of patients. This could increase the effectiveness of available drugs and allow for the evaluation of new combinations and new targets. The main pathways and molecules under study are the IDO inhibitor, TLR9 agonist, STING, LAG-3, TIM-3, HDAC inhibitors, pegylated IL-2 (NKTR-214), GITR, and adenosine pathway inhibitors, among others (there are currently about 3000 trials that are evaluating immunotherapeutic combinations in different tumors). Other promising strategies are cancer vaccines and oncolytic viruses. Another approach is to isolate and remove immune cells (DCs, T cells, and NK cells) from the patient's blood or tumor infiltrates, add specific gene fragments, expand them in culture with growth factors, and re-inoculate into the same patient. TILs, TCR gene transfer, and CAR-T therapy follow this approach. In this article, we give an overview over the current status of melanoma therapies, the clinical rationale for choosing treatments, and the new immunotherapy approaches.

Progress of targeted therapy and immunotherapy for advanced melanoma

Targeted therapeutic strategies for melanoma

Progress in chemotherapy for malignant melanoma

Non-Surgical Treatment Methodologies and Prevention for Malignant Melanoma

Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma

Advances in treatment of melanoma with immunotherapy

Immunotherapy and delivery systems for melanoma

Signal pathways of melanoma and targeted therapy

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Research Advances in the Treatment of Melanoma by Treat Melanoma.

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes

Development of Melanoma Therapy in 2010

Progress on the treatment of BRAF-mutated melanoma

Advancements in Melanoma Therapies: From Surgery to Immunotherapy

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Interaction of Molecular Alterations with Immune Response in Melanoma

Pathogenesis, Diagnosis, and Therapeutic Advances

Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review

Multifunctional Nanoparticle Approach for Targeting Melanoma